File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome

TitleOutcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome
Authors
KeywordsMyelodysplastic syndrome
Acute myeloid leukemia
Therapy-related
Issue Date2006
Citation
Pediatric Blood and Cancer, 2006, v. 47, n. 7, p. 931-935 How to Cite?
AbstractBackground. Therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) carry a poor prognosis. We analyzed the results of allogeneic HSCT in 38 children to determine which factors, if any, affected outcome. Procedure. The effects of demographic, donor, and disease-related factors were analyzed to determine their effects on overall and disease-free survival (OS, DFS), relapse, and non-relapse mortality (NRM). Results. OS and DFS for t-AML and t-MDS were similar. Three-year OS and EFS were the same (15.4 ± 5.8%) and the 3-year NRM was 59.6 ± 8.4%. The 1-year cumulative risk of grade III-IV acute graft-versus-host disease (CVHD) and relapse were 23.7 ± 7.0% and 18.7 ± 6.5%, respectively. The percentage of pre-transplant bone marrow (BM) blasts was positively associated with relapse (P = 0.05), while the percentage of BM blasts at diagnosis of therapy-related disease tended to associate with NRM (P = 0.07). Alternative donor and matched sibling donor grafts had similar outcomes. NRM was higher among patients who did not develop acute CVHD as compared to those with grade 1-2 acute CVHD (69.2 ± 14.2% vs. ± 12.7%, respectively), while NRM was 100% in patients with grade III-IV acute CVHD (P = 0.007). Conclusions. The percentage of BM blasts is associated with relapse in these disorders. High rates of NRM negatively impact the outcome of allogeneic HSCT for children with t-AML and t-MDS. Future studies should focus on reducing NRM. © 2005 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/294417
ISSN
2020 Impact Factor: 3.167
2020 SCImago Journal Rankings: 1.116
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWoodard, Paul-
dc.contributor.authorBarfield, Raymond-
dc.contributor.authorHale, Gregory-
dc.contributor.authorHorwitz, Edwin-
dc.contributor.authorLeung, Wing-
dc.contributor.authorRibeiro, Raul-
dc.contributor.authorRubnitz, Jeffrey-
dc.contributor.authorSrivistava, Deo Kumar-
dc.contributor.authorTong, Xin-
dc.contributor.authorYusuf, Usman-
dc.contributor.authorRaimondi, Susana-
dc.contributor.authorPui, Ching Hon-
dc.contributor.authorHandgretinger, Rupert-
dc.contributor.authorCunningham, John M.-
dc.date.accessioned2020-12-03T08:22:41Z-
dc.date.available2020-12-03T08:22:41Z-
dc.date.issued2006-
dc.identifier.citationPediatric Blood and Cancer, 2006, v. 47, n. 7, p. 931-935-
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/294417-
dc.description.abstractBackground. Therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) carry a poor prognosis. We analyzed the results of allogeneic HSCT in 38 children to determine which factors, if any, affected outcome. Procedure. The effects of demographic, donor, and disease-related factors were analyzed to determine their effects on overall and disease-free survival (OS, DFS), relapse, and non-relapse mortality (NRM). Results. OS and DFS for t-AML and t-MDS were similar. Three-year OS and EFS were the same (15.4 ± 5.8%) and the 3-year NRM was 59.6 ± 8.4%. The 1-year cumulative risk of grade III-IV acute graft-versus-host disease (CVHD) and relapse were 23.7 ± 7.0% and 18.7 ± 6.5%, respectively. The percentage of pre-transplant bone marrow (BM) blasts was positively associated with relapse (P = 0.05), while the percentage of BM blasts at diagnosis of therapy-related disease tended to associate with NRM (P = 0.07). Alternative donor and matched sibling donor grafts had similar outcomes. NRM was higher among patients who did not develop acute CVHD as compared to those with grade 1-2 acute CVHD (69.2 ± 14.2% vs. ± 12.7%, respectively), while NRM was 100% in patients with grade III-IV acute CVHD (P = 0.007). Conclusions. The percentage of BM blasts is associated with relapse in these disorders. High rates of NRM negatively impact the outcome of allogeneic HSCT for children with t-AML and t-MDS. Future studies should focus on reducing NRM. © 2005 Wiley-Liss, Inc.-
dc.languageeng-
dc.relation.ispartofPediatric Blood and Cancer-
dc.subjectMyelodysplastic syndrome-
dc.subjectAcute myeloid leukemia-
dc.subjectTherapy-related-
dc.titleOutcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/pbc.20596-
dc.identifier.pmid16155933-
dc.identifier.scopuseid_2-s2.0-33750444951-
dc.identifier.volume47-
dc.identifier.issue7-
dc.identifier.spage931-
dc.identifier.epage935-
dc.identifier.eissn1545-5017-
dc.identifier.isiWOS:000241803700013-
dc.identifier.issnl1545-5009-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats